The Effect of Soya Foods on Cognitive Function and Menopausal Symptoms in Postmenopausal Women.

NCT ID: NCT03561662

Last Updated: 2018-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-14

Study Completion Date

2018-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants will be randomly assigned to one of three treatment groups to receive soyafoods (Alpro drinks) providing a low (\<10 mg), medium (35mg) or high-dose (60 mg) of isoflavones daily for a period of 12 weeks. The group receiving \<10mg isoflavones daily will serve as a low-dose control group. Women will be asked to avoid consuming any additional soya foods during the study.

Dietary intake will be assessed at baseline using the validated food frequency questionnaire a 4 day food diary will be completed at baseline and post-intervention. Weight and height will be measured and a general health \& lifestyle questionnaire will also be completed by participants at baseline. Cognitive function will be assessed at baseline and post-intervention using the well validated and widely used computerised test battery system. Menopausal symptoms, quality of life, mood, stress and coping will also be assessed.

Plasma concentrations of the soya isoflavones genistein and daidzein will be measured to assess compliance. Circulating concentrations of equol (a daidzein metabolite), will also be measured to investigate associations between equol and cognition and menopausal symptoms as a potential mechanism for the efficacy of soya.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low isoflavone

Alpro soya drinks containing 10 mg isoflavones per day

Group Type ACTIVE_COMPARATOR

Alpro soya drinks

Intervention Type DIETARY_SUPPLEMENT

12 weeks

Medium isoflavone

Alpro soya drinks containing 35 mg isoflavones per day

Group Type ACTIVE_COMPARATOR

Alpro soya drinks

Intervention Type DIETARY_SUPPLEMENT

12 weeks

High isoflavone

Alpro soya drinks containing 60 mg isoflavones per day

Group Type ACTIVE_COMPARATOR

Alpro soya drinks

Intervention Type DIETARY_SUPPLEMENT

12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpro soya drinks

12 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* apparently healthy
* within 7 years postmenpopausal with the absence of vaginal bleeding for at least 1 year
* ≥ 24 in mini mental state examination
* not suffering from psychiatric distress as assessed using GHQ28 questionnaire

Exclusion Criteria

* surgically induced menopause
* habitual consumers of soys foods (\> 2 serves/week)
* currently using hormone therapy
* currently on isoflavone supplements
* antibiotics use within last 3 months
* use of psychoactive medication
* history of CVD, cancer, diabetes, thyroid, renal or kidney disease, alcohol or drug abuse
* red-green colour blindness
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alpro Foundation

OTHER

Sponsor Role collaborator

University of Ulster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Human Intervention Studies Unit, Ulster University

Coleraine, Co.Londonderry, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UREC/15/0025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.